These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19536846)

  • 21. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
    Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
    Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
    Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of bryostatin 1 and gemcitabine.
    El-Rayes BF; Gadgeel S; Shields AF; Manza S; Lorusso P; Philip PA
    Clin Cancer Res; 2006 Dec; 12(23):7059-62. PubMed ID: 17145828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
    Pereira J; Bellesso M; Pracchia LF; Neto AE; Beitler B; de Almeida Macedo MC; Dias LC; Dorlhiac-Llacer PE; Dulley FL; Chamone D
    Leuk Res; 2006 Jun; 30(6):681-5. PubMed ID: 16288806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
    Melani C; Dowdell K; Pittaluga S; Dunleavy K; Roschewski M; Song JY; Calattini S; Kawada JI; Price DA; Chattopadhyay PK; Roederer M; Lucas AN; Steinberg SM; Jaffe ES; Cohen JI; Wilson WH
    Lancet Haematol; 2023 May; 10(5):e346-e358. PubMed ID: 37011643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
    Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
    Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
    Peterson AC; Harlin H; Karrison T; Vogelzang NJ; Knost JA; Kugler JW; Lester E; Vokes E; Gajewski TF; Stadler WM;
    Invest New Drugs; 2006 Mar; 24(2):141-9. PubMed ID: 16514482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
    Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
    Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
    Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
    J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
    Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
    Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.
    Iriyama N; Takahashi H; Hatta Y; Miura K; Kobayashi Y; Kurita D; Hirabayashi Y; Hojo A; Kodaira H; Yagi M; Kiso S; Uchino Y; Nakagawa M; Kusuda M; Kobayashi S; Horikoshi A; Kura Y; Yamazaki T; Sawada U; Takeuchi J
    Oncol Rep; 2013 Feb; 29(2):805-11. PubMed ID: 23166041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
    Kagami Y; Yamamoto K; Shibata T; Tobinai K; Imaizumi Y; Uchida T; Shimada K; Minauchi K; Fukuhara N; Kobayashi H; Yamauchi N; Tsujimura H; Hangaishi A; Tominaga R; Suehiro Y; Yoshida S; Inoue Y; Suzuki S; Tokuhira M; Kusumoto S; Kuroda J; Yakushijin Y; Takamatsu Y; Kubota Y; Nosaka K; Morishima S; Nakamura S; Ogura M; Maruyama D; Hotta T; Morishima Y; Tsukasaki K; Nagai H
    Cancer Sci; 2020 Oct; 111(10):3770-3779. PubMed ID: 32767806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.